A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Clavulanic acid (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2011 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has not been met, according to a Rexahn Pharmaceuticals media release.
    • 23 Jun 2011 Status changed from recruiting to active, no longer recruiting, according to information in a Rexahn Pharmaceuticals media release.
    • 06 May 2011 Rexahn has enrolled 200 patients (66% of the planned total number); recruitment is ongoing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top